Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Neutral 65.7%

Neg 0% Neu 65.7% Pos 0%

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.